**Supplementary Table 8. Analysis of risk factors affecting 12-week prognosis in study participants**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Univariate analysis | *P* value | Multivariate analysis |
|  | OR (95% CI) |  | OR (95% CI) |
| Infection | 3.272 (1.075, 9.959) | 0.037 | 5.271 (1.168, 23.784) |
| PT-INR | 4.640 (2.498, 15.234) | 0.048 |  |
| COSSH-ACLF II score | 4.781 (3.258, 12.312) | 0.018 |  |
| ΔPT-INR (2W) | 0.004 (0.002, 0.056) | 0.002 |  |
| ΔNEU% (2W) | 0.001 (0.000, 0.132) | 0.006 |  |
| ΔMELD score(2W) | 0.008 (0.002, 0.036) | 0.001 | 0.006 (0.002, 0.139) |
| ΔCOSSH-ACLF II score(2W) | 0.001 (0.000, 0.011) | 0.001 |  |

OR: odds ratio; CI: confidence interval; PT, prothrombin time; INR, international normalized ratio; NEU, neutrophil; MELD, model for end-stage liver disease; COSSH-ACLF, Chinese Group on the Study of Severe Hepatitis B-Acute-on-Chronic Liver Failure.